Completed PHASE2 INTERVENTIONAL NCT00001873

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Chronic Lymphocytic Leukemia Graft vs Host Disease Hematologic Neoplasm Multiple Myeloma Myelodysplastic Syndrome

Interventions Isolex 300i plus MoAbs

Updated 7 times since 2017 Last updated: Sep 25, 2018 Started: Feb 22, 1999 Primary completion: Dec 28, 2007 Completion: Jun 13, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Lymphocytic Leukemia and Graft vs Host Disease, this trial is completed. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 7 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Oct 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States